Vaneuza Araújo Moreira Funke

Universidade Federal do Paraná

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ricardo Pasqüini

Hospital de Clínicas Universidade Federal do Paraná

Carmem Bonfim

Hospital de Clínicas Universidade Federal do Paraná

D.C. Setubal

Universidade Federal do Paraná

Marco A. Bitencourt

Hospital de Clínicas Universidade Federal do Paraná

Samir Kanaan Nabhan

Hospital de Clínicas Universidade Federal do Paraná

Nelson Hamerschlak

Hospital Israelita Albert Einstein

Afonso Celso Vigorito

Universidade Estadual de Campinas (UNICAMP)

Mary E.D. Flowers

Fred Hutch Cancer Center

Fernando Barroso Duarte

Hospital Universitário Walter Cantídio

Maria Cláudia Rodrigues Moreira

Instituto Nacional do Câncer

Cooperative Institutions

Universidade Federal do Paraná

174

Hospital de Clínicas Universidade Federal do Paraná

141

Universidade de São Paulo

Hospital Israelita Albert Einstein

Universidade Estadual de Campinas (UNICAMP)

Clinical Research Management

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Inserm

Fred Hutch Cancer Center

Universidade Federal de São Paulo

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Effects of Steroid Hormones on Replication of Murine Sarcoma Virus in Mouse Embryo Cultures

Experimental Biology and Medicine (1975)

Shalom Z. Hirschman Vaneuza Araújo Moreira Funke

The androgenic steroid hormone, testosterone, inhibited focus formation by the murine Moloney sarcoma virus in mouse embryo cells. The inhibition of focus formation was enhanced by cyclic AMP. Although focus formation was inhibited, there was no inhibition of viral replication. The glucogenic adrenal corticosteroids, cortisol and dexamethasone, and 17-beta-estradiol and progesterone did not affect focus formation by MuSV(M).

Steroid hormone

10.3181/00379727-149-38900

Cite

Citations (1)

Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival

Transplantation and Cellular Therapy (2023)

Afonso Celso Vigorito Eliana Cristina Martins Miranda Vergílio Antônio Rensi Colturato Vaneuza Araújo Moreira Funke Giancarlo Fatobene

Failure-free survival (FFS), defined as the absence of new systemic treatment, recurrence of original malignancy and mortality not associated with recurrence after allogeneic hematopoietic stem cell transplantation (HCT), is a robust clinical measure to interpret results of initial systemic treatment of chronic graft-versus-host disease (cGVHD). We evaluate FFS after initial treatment of cGVHD in a mixed-race cohort from a resource-constrained country. This retrospective study included 354 consecutive patients after their first HCT between January 2014 and August 2020, who received initial systemic treatment for moderate or severe cGVHD at 13 Brazilian centers. Cox regression models were used to identify risk factors for treatment failure. The overall median follow-up among survivors was 28 months (range 1-71) after initial treatment. FFS was 89% at 6 months, 71% at 1 year and 52% at 2 years. New systemic treatment was the major cause of failure. In multivariable models, prior grades II-IV acute GVHD, a National Institutes of Health severity score of 3 in liver, gastrointestinal tract or lung involvement, and onset of initial treatment of cGVHD within 12 months after transplantation were all associated with an increased risk of treatment failure. Our results could serve as a benchmark for the design of future clinical trials evaluating initial treatment of cGVHD in resource-constrained locations.

10.1016/j.jtct.2023.01.007

Cite

Citations (0)

Current use and outcomes of hematopoietic stem cell transplantation: Brazilian summary slides - 2023

JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (2023)

Anderson João Simione Heliz Regina A. Neves Cinthya Corrêa da Silva Paula Moreira da Silva Sabaini Bruna Letícia da Silva Santos Geraldo

The first hematopoietic stem cell transplantation (HSCT) program in Latin America started in 1979 at the federal university hospital in Curitiba, Paraná, Brazil. Over the years, the number of centers performing transplants in our country has increased tremendously, generating the need to know the results of this treatment modality. Understanding the HSCT scenario in Brazil is still challenging, since not all Brazilian centers report data to the Center for International Blood and Marrow Research (CIBMTR). Despite the improvement in the number of reporting centers over the past few years, infrastructure and trained data managers are still lacking. The partnership between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the CIBMTR enabled the establishment of the Hematopoietic Stem Cell Transplantation Brazilian Registry (HSCTBR), using the CIBMTR Data Back to Center (DBtC) tool to retrieve Brazilian HSCT data in a standardized and organized way. Since then, it has been possible to gather country-level data on HSCT demographics and transplant outcomes. Between 2012 and 2022, complete information on 9,868 transplants were reported to the CIBMTR from 40 Brazilian transplant centers. The consolidation of the HSCTBR using CIBMTR infrastructure allowed the development and regular update of the Brazilian Summary Slides. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (US) Summary Slides. In this paper we present the 2023 SBTMO-CIBMTR Summary Slides prepared by the SBTMO data managers (GD-SBTMO).

Bone transplantation

10.46765/2675-374x.2023v4n2p200

Cite

Citations (0)

11 / Chronic graft-versus-host disease: survival impact on patients with Severe Aplastic Anemia (SAA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)

Gláucia Tagliari Bovo Priscila Fernanda Vaneuza Araújo Moreira Funke

SAA and PNH are rare and potentially fatal diseases which can be treated by allogeneic hematopoietic stem cell transplantation (HSCT).One of the most common complications after HSCT is chronic graft-versus-host disease (cGVHD).In the context of malignant diseases cGVHD can also bring the benefit of graft-versus-leukemia effect.However, in benignant diseases there is not such benefit Objective

Paroxysmal nocturnal hemoglobinuria

Aplastic anemia

10.26226/morressier.5b3b802db1b87b000eced96a

Cite

Citations (0)

Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Comparison Between Myeloablative and Reduced Intensity Conditioning

Biology of Blood and Marrow Transplantation (2013)

Vaneuza Araújo Moreira Funke Vanessa Fiorini Furtado Gustavo Rengel dos Santos Leticia A. Sinamura Tamila Fagundes

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is indicated for patients with intermediate or high risk primary Myelofibrosis (MF), and also in patients with Policitemia Vera or Essential Thrombocythemia who have progressed to high risk MF. The results for allogeneic HSCT with myeloablative conditioning seem to be better for patients younger than 45 years, determining lower relapse risk. However, Reduced Intensity Conditioning (RIC) for patients between 45 and 65 years-old has shown to be a promising strategy, with less mortality related to the procedure.

10.1016/j.bbmt.2012.11.416

Cite

Citations (0)

Results of a Distance-Learning Tutorial for Brazilian Centers on How to Insert Data in the CIBMTR Registry

Biology of Blood and Marrow Transplantation (2018)

Cinthya Correa Silva Heliz Regina A. Neves Anderson João Simioni Marcelo C. Pasquini Vergilio A.R. Colturato

Background: According to the Brazilian Organ Transplantation Association (ABTO), 2,187 hematopoietic stem cell transplantation (HSCT) were performed in Brazil in 2016. The Center for Blood and Marrow Transplant Research (CIBMTR) is an international network of bone marrow transplantation centers that maintains a large, public, clinical database focused on outcomes. Objectives: We aimed to analyze the results of a tutorial for Brazilian transplant centers on the insertion of data in the CIBMTR. Methods: Three Brazilian transplantation centers developed and implemented a web-based distance-learning tutorial from June 1, 2016 to February 2, 2017, teaching center representatives to complete the TED (Transplant Essential Data) forms, and encouraging national centers to report data to the CIBMTR. The results were compiled from the Adobe Connect and CIBMTR databases. An online satisfaction survey was performed using 0-10 scores and asking if the participant would indicate the course to a colleague. The survey also evaluated the applicability of the courses to the routine. Results: The course "Guide to Pre- and Post- Transplant Data Completion" had the participation of 55 Brazilian centers, and 110 representatives completed module #1 (Pre-TED) and 27 completed module #2 (Post-TED form). Nurses comprised 24% (33) of participants. Most satisfaction scores were 8, 9 and 10 (Table 1), for each item, and 72.4% (35) of participants would indicate the Pre-TED course and 93.4% (14) the post-TED to a co-worker. The content was considered applicable to the routine for 66.7% (28, for the Pre-TED) and 86.7% (13, post-TED). In the first semester of 2017, a new center has already joined the CIBMTR databank.Table 1Positive Responses on Satisfaction with the Online Distance Tutorial: Number of Participants Who Scored 8-10 in Each ItemPre-TEDPost-TEDPositive responses to itemsN(%)N(%)Would you indicate this course to a colleague?3572.41493.4Is the tutorial content up-to-date?3685.615100Can you use what you learned in your routine?2866.71386.7Were the educational strategies good?3073.21493.4Were the access and navigation easy?3380.51386.7Were the additional resources such as videos and audios accessible?2970.71386.6 Open table in a new tab Conclusion: The distance-learning tutorial positively influenced the registration of data to the CIBMTR, demonstrated by the number of centers participating in the training, the indication of the course to another person and the increase of an active center in the CIBMTR database. The recognition of the course, at national and international levels, strengthens the investments in this type of education initiative, for new centers as well as for those who already carry out this registering activity.

Bone transplantation

10.1016/j.bbmt.2017.12.561

Cite

Citations (1)

In the Molecular Classification Era, Can We Still Use IPSS-R in HSCT of MDS Patients?

Transplantation and Cellular Therapy (2023)

Fernando Barroso Duarte Talyta Ellen de Jesus dos Santos Sousa Vaneuza Araújo Moreira Funke Virgílio Antônio Rensi Colturato Prof. Nelson Hamerschlak

Management of acute lymphoblastic leukemia (ALL) in a socioeconomically vulnerable population without ready access to a hematopoietic stem cell transplant (HCT) center and clinical trials is challenging. Data regarding the outcomes of such patients are sparse.This retrospective analysis included 90 consecutive patients with ALL who presented to Harbor-UCLA between 2003 and 2018. The primary objective was overall survival (OS), whereas secondary objectives included leukemia-free survival, toxicities of therapy, and referral for HCT and incidence of successful HCT.Most patients were male (56.7%) and Hispanic (72.2%). The median age of diagnosis was 36 years (range, 18-63 years). The median OS was 26.8 months (95% confidence interval [CI], 17.4-59.0 months). In patients who achieved complete remission with therapy, the median leukemia-free survival was 16.4 months. Fifty percent of patients experienced at least 1 episode of bacteremia, and nearly 25% of patients developed an invasive fungal infection. Thirty-six percent (n = 32) of patients were referred for HCT. The referral rate increased over time, which led to improved OS in patients who underwent evaluation at a tertiary cancer center (hazard ratio, 0.44; 95% CI, 0.21-0.89; P = .02). Patients who underwent HCT had significantly better OS compared with those who did not (OS not reached vs. 21.9 months; hazard ratio, 0.16; 95% CI, 0.04-0.68; P = .01).Risk stratification and evidence-based treatment approaches are important for patients with ALL treated in a resource-limited setting. Most patients can be induced successfully and achieve complete remission with therapy. Partnership with a cancer center with early referral for HCT can facilitate curative HCT to be performed.

10.1016/s2666-6367(23)00472-4

Cite

Citations (0)

Access to oral care before hematopoietic stem cell transplantation: understand to improve

Supportive Care in Cancer (2016)

Marta Aparecida Alberton Nuernberg Samir Kanaan Nabhan Carmem Bonfim Vaneuza Araújo Moreira Funke Cassius Carvalho Torres‐Pereira

10.1007/s00520-016-3142-1

Cite

Citations (16)

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience

Blood (2020)

Katia B Pagnano Ana Carolina Mourão Toreli Leila Martins Perobelli Acy TS Quixada Fernanda Salles Seguro

10.1182/blood-2020-138563

Cite

Citations (0)

Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients

European Journal Of Haematology (2015)

Paulo Vidal Campregher Nelson Hamerschlak Vergílio Antônio Renzi Colturato Marcos Augusto Mauad Mair Pedro de Souza

The objective of this study was to compare the major transplant outcomes between patients receiving hematopoietic stem cell transplantation (HSCT) from bone marrow (BM) or peripheral blood stem cells (PBSC).All consecutive HSCT patients using BM or PBSC from an HLA-matched related donors for haematological malignancies after high intensity conditioning at seven Brazilian transplant centres between January 2008 and December 2009 were retrospectively evaluated.In the study period, 334 patients were treated in the centres and included in the evaluation. The cumulative incidence of grades II-IV and III-IV acute graft-versus-host disease (GVHD) at one year was 36.7% and 9.7% for BM recipients and 34.4% and 15.1% for PBSC recipients, respectively (not statistically different). The cumulative incidence of chronic GVHD at three years was 53.7% and 79.8% (HR 1.93; 95% CI 1.38-2.69, P < 0.001) for BM and PBSC, respectively. Median overall survival was 2.85 and 2.39 years for BM and PBSC recipients, respectively (HR 1.19; 95% CI, 0.84-1.68, P = 0.34).Our results confirm previous findings of increased chronic GVHD incidence in patients receiving PBSC when compared to patients receiving BM as the graft source in HSCT. Acute GVHD incidence, progression-free survival and overall survival were not different between the groups.

Cumulative incidence

10.1111/ejh.12508

Cite

Citations (18)